The overlap of symptomatic dimensions between frontotemporal dementia and several psychiatric disorders that appear in late adulthood

Pose, María Ángeles; Cetkovich, Marcelo; Gleichgerrcht, Ezequiel; Ibáñez, Agustín; Torralva, Teresa; Manes, Facundo

doi:10.3109/09540261.2013.769939

Cited by 65 publications

(55 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinical evaluation is crucial, but clinicians encounter an overlap of symptoms between bvFTD, psychiatric affective disorders and AD [6]. For this reason, the clinical evaluation must be completed with imaging markers.…”

Section: Diagnosis Of Bvftd Patientsmentioning

confidence: 99%

Evaluating Behavior in Mouse Models of the Behavioral Variant of Frontotemporal Dementia: Which Test for Which Symptom?

Vernay

Sellal²,

Frydman³

2015

Neurodegener Dis

View full text Add to dashboard Cite

The behavioral variant of frontotemporal dementia (bvFTD) is a neurodegenerative disease affecting people in their early sixties, characterized by dramatic changes in individual and social behavior. Despite the heterogeneity in the presentation of the clinical symptoms of bvFTD, some characteristic changes can be highlighted. Social disinhibition, changes in food preferences as well as loss of empathy and apathy are commonly described. This is accompanied by a characteristic and dramatic atrophy of the prefrontal cortex with the accumulation of protein aggregates in the neurons in this area. Several causative mutations in different genes have been discovered, allowing the development of transgenic animal models, especially mouse models. In mice, attention has been focused on the histopathological aspects of the pathology, but now studies are taking interest in assessing the behavioral phenotype of FTD models. Finding the right test corresponding to human symptoms is quite challenging, especially since the frontal cortex is much less developed in mice than in humans. Although challenging, the ability to detect relevant prefrontal cortex impairments in mice is crucial for therapeutic approaches. In this review, we aim to present the approaches that have been used to model the behavioral symptoms of FTD and to explore other relevant approaches to assess behavior involving the prefrontal cortex, as well as the deficits associated with FTD.

show abstract

Section: Diagnosis Of Bvftd Patientsmentioning

confidence: 99%

Evaluating Behavior in Mouse Models of the Behavioral Variant of Frontotemporal Dementia: Which Test for Which Symptom?

Vernay

Sellal²,

Frydman³

2015

Neurodegener Dis

View full text Add to dashboard Cite

show abstract

“…bvFTD has a broad differential diagnosis of both neurodegenerative and psychiatric disorders, resulting in a similar late-onset behavioral syndrome [4,5,6,7,8,9,10,11,12,13]. Although biomarkers take a prominent position in the present FTDC criteria, it is still unclear how they can distinguish between bvFTD and a representative control group [3].…”

Section: Introductionmentioning

confidence: 99%

Impact of Imaging and Cerebrospinal Fluid Biomarkers on Behavioral Variant Frontotemporal Dementia Diagnosis within a Late-Onset Frontal Lobe Syndrome Cohort

Krudop¹,

Dols

Kerssens

et al. 2015

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

Background: The criteria for behavioral variant frontotemporal dementia (bvFTD) incorporate MRI and [¹⁸F]-FDG-PET. Cerebrospinal fluid (CSF) analysis is merely advised for excluding Alzheimer's disease. Aims: We aimed to assess the impact of biomarkers on diagnostic certainty and contingent changes of bvFTD diagnosis within the clinically relevant neuropsychiatric differential diagnosis of subjects with a late-onset frontal lobe syndrome (LOF). Methods: We included 137 patients with LOF, aged 45-75 years, 72% males. Biomarker disclosure was considered contributing after any substantial difference in diagnostic certainty or a diagnostic change. Percentages of contributing biomarkers were compared between three major diagnostic groups (bvFTD, psychiatry, other neurological disorders). Certainty levels in stable diagnostic groups were compared to those with a diagnostic change. Results: Biomarkers contributed in 53, 60 and 41% of the LOF patients for MRI, [¹⁸F]-FDG-PET and CSF, respectively. Biomarkers changed the diagnosis in 14% of cases towards bvFTD and in 13% from bvFTD into an alternative. Those that changed had a lower level of a priori diagnostic certainty compared to stable diagnoses. Conclusion: Our study not only supports the widely accepted use of MRI and [¹⁸F]-FDG-PET in diagnosing or excluding bvFTD, but also shows that CSF biomarkers aid clinicians in the diagnostic process.

show abstract

“…Recent reviews have suggested some "red flags" that should raise suspicions for an FTD diagnosis, including cognitive dysfunction, in particular aphasia or executive dysfunction, lack of distress in the setting of mood or anxiety disorders, progressive impairment, lack of treatment response, and unusual psychiatric features, such as compulsions without obsessions, sustained manic states without grandiosity or euphoria, or schizophrenia without complex delusions or hallucinations. 8,24 These criteria seem reasonable and are relevant to some of our cases, for instance, Case 1 who showed lack of distress and compulsions without obsessions. Cases 2-4 appear to have been more typical, and the sensitivity of these criteria may not have been adequate to identify them in the earliest phases of illness.…”

Section: Discussionmentioning

confidence: 99%

P1‐196: Frontotemporal Dementia and Psychiatric Illness: Emerging Clinical and Biological Links in Gene Carriers

Block

Sha

Karydas

et al. 2014

Alzheimer's & Dementia

View full text Add to dashboard Cite

Objective-To describe psychiatric presentations in individuals with genetic mutations causing frontotemporal dementia (FTD).Design-Case descriptions from five carriers of FTD-related gene mutations with symptoms associated with non-neurodegenerative psychiatric disease.Setting-A comprehensive research program investigating genetic and non-genetic FTD at the University of California, San Francisco Memory and Aging Center. Participants-Three probands and two non-proband gene carriers.Measurements-Medical history and neurological examination, neuropsychological testing, MR and/or PET imaging, and a genetic analysis to screen for dementia-related mutations. Genetic status was unknown at the time of initial evaluation.

show abstract

The overlap of symptomatic dimensions between frontotemporal dementia and several psychiatric disorders that appear in late adulthood

Cited by 65 publications

References 99 publications

Evaluating Behavior in Mouse Models of the Behavioral Variant of Frontotemporal Dementia: Which Test for Which Symptom?

Evaluating Behavior in Mouse Models of the Behavioral Variant of Frontotemporal Dementia: Which Test for Which Symptom?

Impact of Imaging and Cerebrospinal Fluid Biomarkers on Behavioral Variant Frontotemporal Dementia Diagnosis within a Late-Onset Frontal Lobe Syndrome Cohort

P1‐196: Frontotemporal Dementia and Psychiatric Illness: Emerging Clinical and Biological Links in Gene Carriers

Contact Info

Product

Resources

About